<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331640</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-PAK-0116</org_study_id>
    <nct_id>NCT03331640</nct_id>
  </id_info>
  <brief_title>A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy</brief_title>
  <acronym>PANTHEON</acronym>
  <official_title>A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy: An AIO Phase II Cross Over Trial (PANTHEON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy of second and third line therapies (OFF vs.&#xD;
      FOLFIRI) in a sequential cross-over design in patients pretreated with&#xD;
      nab-paclitaxel/gemcitabine first line.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives are assessment of safety and feasibility of the sequential cross-over&#xD;
      treatment approach for advanced treatment lines in PDAC. 204 patients will be randomized into&#xD;
      the treatments arms. Cross-over will take place after progress during second line therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival during 2nd line therapy (PFS2)</measure>
    <time_frame>49 months</time_frame>
    <description>Progression-free survival time from randomization till progress during second line therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Metastatic Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>OFF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OFF</intervention_name>
    <description>OFF:&#xD;
5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d</description>
    <arm_group_label>OFF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI Protocol</intervention_name>
    <description>Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w</description>
    <arm_group_label>FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent and any locally-required authorization (EU Data Privacy&#xD;
             Directive in the EU) obtained from the subject prior to performing any&#xD;
             protocol-related procedures, including screening evaluations&#xD;
&#xD;
          2. Age ≥ 18 years at time of study entry&#xD;
&#xD;
          3. Unresectable adenocarcinoma of the pancreas previously treated in the palliative&#xD;
             setting with gemcitabine and nabpaclitaxel (Abraxane®)&#xD;
&#xD;
          4. Adequately documented recurrence and disease status after/under 1st line (Best&#xD;
             response, duration of treatment, time to progression, preexisting PNP and other side&#xD;
             effects)&#xD;
&#xD;
          5. Radiologically confirmed disease progression during 1st-line therapy and measurable&#xD;
             reference cancer site(s) as defined by RECIST1.1&#xD;
&#xD;
          6. Randomization and start of 2nd-line treatment possible within 4 weeks after&#xD;
             radiologically documented disease progression during 1st-line therapy&#xD;
&#xD;
          7. ECOG performance status 0-2&#xD;
&#xD;
          8. No prior radiotherapy&#xD;
&#xD;
          9. Adequate blood count, liver-enzymes, and renal function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (&gt; 1500 per mm3)&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L (&gt;100,000 per mm3)&#xD;
&#xD;
               -  AST (SGOT)/ALT (SGPT) &lt; 2.5 x institutional upper limit of normal unless liver&#xD;
                  metastases are present, in which case it must be &lt; 5x ULN&#xD;
&#xD;
               -  Serum creatinine CL ≥ 60 mL/min calculations according to local standard&#xD;
&#xD;
               -  Bilirubin &lt; 3 ULN&#xD;
&#xD;
         10. Female subjects must either be of non-reproductive potential (ie, post-menopausal by&#xD;
             history: ≥ 60 years old and no menses for ≥ 1 year without an alternative medical&#xD;
             cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history&#xD;
             of bilateral oophorectomy) or must have a negative serum pregnancy test upon study&#xD;
             entry&#xD;
&#xD;
         11. Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious cardiovascular disease (eg, unstable coronary artery disease or myocardial&#xD;
             infarction within 3 months prior to study start)&#xD;
&#xD;
          2. Preexisting polyneuropathy (PNP) ≥ grade 3 [National Cancer Institute Common Toxicity&#xD;
             Criteria grade 3 or 4 sensory or motor neuropathy]&#xD;
&#xD;
          3. Prior or concurrent malignancy (other than pancreatic cancer) which either progresses&#xD;
             or requires active treatment. Exceptions are: basal cell cancer of the skin&#xD;
&#xD;
          4. History of DPD deficiency&#xD;
&#xD;
          5. Morbus Gilbert&#xD;
&#xD;
          6. History of hypersensitivity to any of the study drugs or any of the constituents of&#xD;
             the products&#xD;
&#xD;
          7. Medication that is known to interfere with any of the agents applied in the trial&#xD;
&#xD;
          8. Female subjects who are pregnant, breast-feeding or male or female patients of&#xD;
             reproductive potential who are not employing an effective method of birth control&#xD;
             (failure rate of less than 1% per year)&#xD;
&#xD;
          9. Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of study treatment or interpretation of patient safety or study results&#xD;
&#xD;
         10. Any medical condition that contraindicates dosing with any of the IMPs or constitutes&#xD;
             a safety risk for the patient including but not limited to:&#xD;
&#xD;
               1. chronic inflammatory bowel disease and/or bowel obstruction.&#xD;
&#xD;
               2. active uncontrolled infection&#xD;
&#xD;
               3. clinically significant bleeding or bleeding diathesis&#xD;
&#xD;
               4. clinically significant stomatitis&#xD;
&#xD;
               5. active ulceration of the gastrointestinal tract&#xD;
&#xD;
         11. Previous enrollment or randomization in the present study (does not include screening&#xD;
             failure)&#xD;
&#xD;
         12. Patient who has been incarcerated or involuntarily institutionalized by court order or&#xD;
             by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG&#xD;
&#xD;
         13. Patients who are unable to consent because they do not understand the nature,&#xD;
             significance and implications of the clinical trial and therefore cannot form a&#xD;
             rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Praxis für Innere Medizin</name>
      <address>
        <city>Friedrichshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>Homepage of the AIO (Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft e.V.)</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

